Human normal immunoglobulin (Baxalta)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman normal immunoglobulin (Baxalta)
Drug Alias NameImmune globulin intravenousImmune globulin (Baxalta)IGSC - BaxaltaIGIV - BaxaltaPolygam LQ +[8] 
ClassificationBiologics > Blood components
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesPurpura, Thrombocytopenic, Idiopathic +[8] 
Global Approved IndicationsImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesPurpura, Thrombocytopenic, Idiopathic +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/04/27
Country/TerritoryCzechiaCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Manufacturing Austria AgBaxter Healthcare Corporation Of Puerto Rico (Utah)Baxalta Innovations Gmbh +[6] 
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesPurpura, Thrombocytopenic, Idiopathic +[7] 
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeJ06BA01
Related LinksN/A